公开(公告)号：US09249171B2

公开(公告)日：2016-02-02

申请号：US14402231

申请日：2013-05-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Adrian Ortiz ,  Tamas Benkovics ,  Zhongping Shi ,  Prashant P. Deshpande ,  Zhiwei Guo ,  David R. Kronenthal ,  Chris Sfouggatakis

IPC: C07H15/20 ,  C07H19/06 ,  C12P19/38 ,  C07D309/10 ,  C07D407/04 ,  C07D307/20

CPC classification number: C07H15/20 ,  C07D307/20 ,  C07D309/10 ,  C07D407/04 ,  C07H19/06 ,  C12P19/385

Abstract: A process for making the compound of Formula I utilizes the starting compound, together with sulfilimine and sulfoxide process steps later on.

Abstract translation: 制备式I化合物的方法利用起始化合物以及稍后的亚硫酰亚胺和亚砜工艺步骤。

公开(公告)号：US20160060252A1

公开(公告)日：2016-03-03

申请号：US14784460

申请日：2014-04-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： William P. Gallagher ,  Prashant P. Deshpande ,  Jun Li ,  Kishta Katipally

IPC: C07D405/04 ,  C07D493/04

CPC classification number: C07D405/04 ,  C07D493/04

Abstract: The NRTI compound festinavir is made using 5-methyluridine as a starting material, followed by Claisen rearrangement.

Abstract translation: 使用5-甲基尿苷作为起始原料制备NRTI化合物festinavir，接着是Claisen重排。

公开(公告)号：US20150140610A1

公开(公告)日：2015-05-21

申请号：US14402231

申请日：2013-05-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Adrian Ortiz ,  Tamas Benkovics ,  Zhongping Shi ,  Prashant P. Deshpande ,  Zhiwei Guo ,  David R. Kronenthal ,  Chris Sfouggatakis

IPC: C07H15/20 ,  C07H19/06 ,  C12P19/38

CPC classification number: C07H15/20 ,  C07D307/20 ,  C07D309/10 ,  C07D407/04 ,  C07H19/06 ,  C12P19/385

Abstract: A process for making the compound of Formula I utilizes the starting compound, together with sulfilimine and sulfoxide process steps later on.

Abstract translation: 制备式I化合物的方法利用起始化合物以及稍后的亚硫酰亚胺和亚砜工艺步骤。

公开(公告)号：US20130303467A1

公开(公告)日：2013-11-14

申请号：US13938763

申请日：2013-07-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jack Z. Gougoutas ,  Hildegard Lobinger ,  Srividya Ramakrishnan ,  Prashant P. Deshpande ,  Jeffrey T. Bien ,  Chiajen Lai ,  Chenchi Wang ,  Peter Riebel ,  John Anthony Grosso ,  Alexandra A. Nirschl ,  Janak Singh ,  John D. DiMarco

IPC: C07H15/207 ,  A61K45/06 ,  A61K31/7034

CPC classification number: C07H15/207 ,  A61K31/7034 ,  A61K45/06 ,  A61P3/10 ,  C07H7/04

Abstract: The present invention relates to physical crystal structures of a compound of the formula I: wherein R1, R2, R2a, R3 and R4 are as defined herein, especially pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Abstract translation: 本发明涉及式I化合物的物理结晶结构：其中R1，R2，R2a，R3和R4如本文所定义，特别是含有化合物I或II结构的药物组合物，其制备方法， 制备方法以及使用这种结构治疗糖尿病等疾病的方法。